Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Amgen And GSK Form Drug Partnership

by Lisa M. Jarvis
August 3, 2009 | A version of this story appeared in Volume 87, Issue 31

Amgen has partnered with GlaxoSmithKline to sell denosumab, a monoclonal antibody in development to treat osteoporosis, in Europe, Australia, New Zealand, and Mexico. GSK will pay $120 million up front and royalties on sales of the drug in those markets. It will also seek approval to commercialize the drug in emerging markets, such as China and India. Amgen is holding on to the rights to the drug in the U.S., where it already has a strong marketing presence. Analysts expect the drug to bring in $2 billion in sales in the U.S. alone by 2014. Denosumab is also being developed to treat cancer, an indication for which Amgen retains exclusive rights.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.